Abstract:Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as TGF-β and PDGFs), cytokines (including TNF-α, IL-1, IL-6, IL-10 and IL-4), and neurohumoral pathways trigger fibrogenic signaling cascades through binding to surface receptors, and activation of downstream signaling cascades. In addition, matricellular macromolecules are deposited in the remodeling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review manuscript discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction (HFrEF and HFpEF), genetic cardiomyopathies and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodeling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.

Transient Receptor Potential (TRP) Channels and Cardiac Fibrosis

Fibroblast Proliferation Alters Cardiac Excitation Conduction and Contraction: a Computational Study.

Progress on role of ion channels of cardiac fibroblasts in fibrosis

Role of TRPM7 in cardiac fibrosis: A potential therapeutic target (Review)

Transient receptor potential in tissue fibrosis

TRPM7-mediated Ca2+ Signals Confer Fibrogenesis in Human Atrial Fibrillation.

TRPM7 is involved in angiotensin II induced cardiac fibrosis development by mediating calcium and magnesium influx.

Cardiac Fibrosis: New Insights into the Pathogenesis

Transient Receptor Potential Vanilloid Subtype 1: A Potential Therapeutic Target for Fibrotic Diseases

Function and therapeutic potential of transient receptor potential ankyrin 1 in fibrosis

Novel Insights into TRPM7 Function in Fibrotic Diseases: a Potential Therapeutic Target.

Ca2+ Signaling in Cardiovascular Fibroblasts

Canonical transient receptor potential 3 channels in atrial fibrillation

EphrinB2 Regulates Cardiac Fibrosis Through Modulating the Interaction of Stat3 and TGF-β/Smad3 Signaling

The role and mechanism of vascular wall cell ion channels in vascular fibrosis remodeling

Cardiac fibrosis.

Cardiac Fibrosis: Cellular Effectors, Molecular Pathways, and Exosomal Roles

K Ca 3.1 Channels Promote Cardiac Fibrosis Through Mediating Inflammation and Differentiation of Monocytes Into Myofibroblasts in Angiotensin II -Treated Rats.

Cardiac Fibrosis: Key Role of Integrins in Cardiac Homeostasis and Remodeling

Crosstalk between the TGF-β and WNT signalling pathways during cardiac fibrogenesis

Epigenetic Regulation of Fibroblasts and Crosstalk between Cardiomyocytes and Non-Myocyte Cells in Cardiac Fibrosis